Pfizer and BioNTech have submitted an application to the U.S. Food and Drug Administration (FDA) requesting the authorization of their bivalent COVID-19 vaccine for use in people 12 years and older. The new formulation combines the original vaccine with one that specifically targets omicron BA.4 and BA.5 subvariants. “Given the ongoing evolution of SARS-CoV-2 and … Continue reading Pfizer submits application for new booster targeting COVID-19 subvariants